In the latest in a series of “Listening Sessions” offered around town by School District Officials in advance of a $2.75 million referendum question, officials said on Monday, March 7 at the Behring ...

We cut our fair value estimate for narrow-moat CSL by 22% to $210 due to our plasma earnings downgrades. However, shares are undervalued. Despite fiercer competition, we think we are more optimistic ...

The Kanakee project builds on the biopharma company’s efforts to increase its U.S. footprint, where it has already spent more than $3 billion, and will focus on producing plasma-derived therapies.

CSL, a global pharmaceutical manufacturer based in Melbourne, Australia, has broken ground on a $1.5 billion expansion of its campus in Kankakee, roughly 60 miles southwest of Chicago. The company has ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5-billion project.  | On Monday, CSL broke ground on an ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Corifact Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

Dublin, March 10, 2026 (GLOBE NEWSWIRE) -- The "Albuminar Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has been added to ResearchAndMarkets.com's offering. The ...

Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

Article Summary Australian biotechnology company to invest $1.5 billion by 2031 to expand Kankakee plasma-processing facility. The expansion will create ...

The Melbourne-based company will build a 330,000-square-foot facility and retain 1,200 existing positions. Construction is ...

Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through ...